Xencor, Inc. announced that company management will present at two upcoming conferences.
MONROVIA, Calif., May 31, 2018 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer, today announced that company management will present at two upcoming conferences:
- Jefferies 2018 Healthcare Conference
Date: Thursday, June 7, 2018
Time: 1:30 p.m. ET
Location: New York, NY
- JMP Securities Life Sciences Conference
Date: Wednesday, June 20, 2018
Time: 1:30 p.m. ET
Location: New York, NY
Live webcasts of both events will be available under “Events & Presentations” in the Investors section of the Company’s website located at http://investors.xencor.com/events.cfm. A replay of the presentations will be posted on the Xencor website approximately one hour after the live events and will be available for 90 days following the presentations.
About Xencor, Inc.
Xencor is a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases and cancer. Currently, 10 candidates engineered with Xencor’s XmAb® technology are in clinical development internally and with partners. Xencor’s internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1 development for the treatment of asthma and allergic diseases; XmAb®14045 in Phase 1 development for acute myeloid leukemia; XmAb®13676 in Phase 1 development for B-cell malignancies; XmAb®18087 in Phase 1 development for the treatment of neuroendocrine tumors and gastrointestinal stromal tumors; and XmAb®20717, XmAb®22841, XmAb®23104 and XmAb®24306 in pre-clinical development for the treatment of multiple cancers. Xencor’s XmAb antibody engineering technology enables small changes to the structure of monoclonal antibodies resulting in new mechanisms of therapeutic action. Xencor partners include Novartis, Amgen, MorphoSys, CSL, Alexion and Boehringer Ingelheim. For more information, please visit www.xencor.com.
CONTACT: Investor Contact: John Kuch, Vice President Finance, Xencor, Tel: 626-737-8013, jkuch@xencor.com Corporate Communications Contact: Jason I. Spark, Canale Communications for Xencor, Tel: 619-849-6005, jason@canalecomm.com
View original content with multimedia:http://www.prnewswire.com/news-releases/xencor-to-present-at-upcoming-investor-conferences-300657688.html
SOURCE Xencor, Inc.
Company Codes: NASDAQ-NMS:XNCR |
